Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Быков Ю.В., Беккер Р.А., Резников М.К. Депрессии и резистентность. М.: ИНФРА-М, 2013. / Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost'. M.: INFRA-M, 2013. [in Russian] 2. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th Ed. Cambridge University Press, 2013. ISBN 978–1107686465. 3. Данилов Д.С. Антидепрессанты – селективные ингибиторы обратного нейронального захвата серотонина: 40-летняя история. Неврология, нейропсихиатрия, психосоматика. 2015; 1: 66–74. / Danilov D.S. Antidepressanty – selektivnye ingibitory obratnogo neironal'nogo zakhvata serotonina: 40-letniaia istoriia. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2015; 1: 66–74. [in Russian] 4. Данилов Д.С. История селективных ингибиторов обратного захвата серотонина. Психиатрия и психофармакотерапия. 2015; 17 (5–6): 26–33. / Danilov D.S. The history of selective serotonin reuptake inhibitors. Psychiatry and Psycopharmacotherapy. 2015; 17 (5–6): 26–33. [in Russian] 5. Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 2012; 6: 853–61. 6. Мазо Г.Э., Незнанов Н.Г. Терапевтически резистентные депрессии. СПб.: Береста, 2012. / Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. SPb.: Beresta, 2012. [in Russian] 7. APA Practice Guideline on MDD. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf 8. APA Practice Guideline on Panic Disorder. http://psychiat ryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf 9. APA Practice Guideline on OCD. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd.pdf 10. Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2013; 6: CD001396. 11. Freeman EW, Guthrie KA, Caan B et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305: 267–74. 12. Otto M, Bach FW, Jensen TS et al. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain 2008; 139: 275–83. 13. Brown ES, Howard C, Khan DA, Carmody TJ. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Psychosomatics 2012; 53 (1): 75–80. 14. Изнак А.Ф., Поздеева Е.А., Изнак Е.В. «Чистые» стереоизомеры – новое направление повышения эффективности антидепрессантов (обзор литературы). Обозрение психиатрии и мед. психологии. 2008; 1: 8–13. / Iznak A.F., Pozdeeva E.A., Iznak E.V. «Chistye» stereoizomery – novoe napravlenie povysheniia effektivnosti antidepressantov (obzor literatury). Obozrenie psikhiatrii i med. psikhologii. 2008; 1: 8–13. [in Russian] 15. Медведев В.Э., Зуйкова Н.Л. Применение антидепрессанта эсциталопрама (Селектра) в терапии депрессий и тревожных расстройств у пациентов общей медицинской сети. Справочник поликлинического врача. 2010; 9: 70–3. / Medvedev V.E., Zuikova N.L. Primenenie antidepressanta estsitaloprama (Selektra) v terapii depressii i trevozhnykh rasstroistv u patsientov obshchei meditsinskoi seti. Handbook for Practitioners Doctors. 2010; 9: 70–3. [in Russian] 16. Hedges DW, Woon FL. An emerging role for escitalopram in the treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2007; 3 (4): 455–61. 17. Grundmann M, Kacirova I, Urinovska R. Therapeutic monitoring of psychoactive drugs – antidepressants: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159 (1): 35–43. 18. Волель Б.А., Дубницкая Э.Б., Серебряков Е.В. Эсциталопрам – второе поколение селективных ингибиторов обратного захвата серотонина (клиническая эффективность при депрессиях легкой и умеренной степени тяжести). Соц. и клин. психиатрия. 2005; 2 (15): 61–6. / Volel' B.A., Dubnitskaia E.B., Serebriakov E.V. Estsitalopram – vtoroe pokolenie selektivnykh ingibitorov obratnogo zakhvata serotonina (klinicheskaia effektivnost' pri depressiiakh legkoi i umerennoi stepeni tiazhesti). Sots. i klin. psikhiatriia. 2005; 2 (15): 61–6. [in Russian] 19. Leonard B, Taylor D. Escitalopram – translating molecular properties into clinical benefit: reviewing the evidence in major depression. J Psychopharmacol 2010; 24 (8): 1143–52. 20. Yevtushenko VY, Belous AI, Yevtushenko YG et al. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007; 29: 2319–32. 21. Burke WJ, Gergel I, Bose A et al. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–6. 22. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharm 2006; 21: 159–69. 23. Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 2007; 23: 245–50. 24. Сиволап Ю.П. Антидепрессанты в лечении алкоголизма. Журн. неврологии и психиатрии им. С.С.Корсакова. 2012; 112: 32–6. / Sivolap Iu.P. Antidepressanty v lechenii alkogolizma. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2012; 112: 32–6. [in Russian] 25. Bellantuono C, Orsolini L, Bozzi F. The safety profile of escitalopram in pregnancy and breastfeeding. [Article in Italian]. Riv Psichiatr 2013; 48 (6): 407714. 26. Masdrakis VG, Oulis P, Florakis A et al. The safety of the electroconvulsive therapy-escitalopram combination. J ECT 2008; 24 (4): 289–91. 27. Wu J, Chang F, Zu H. Efficacy and safety evaluation of citalopram and doxepin on sleep quality in comorbid insomnia and anxiety disorders. Exp Ther Med 2015; 10 (4): 1303–8. 28. Ensrud KE, Joffe H, Guthrie KA et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause 2012; 19 (8): 848–55. 29. Kim JM, Stewart R, Bae KY et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychol Med 2015; 45 (8): 1641–52. 30. Stein DJ, Lopez AG. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Adv Ther 2011; 28 (11): 1021–37. 31. Todder D, Baune BT. Quality of sleep in escitalopram-treated female patients with panic disorder. Hum Psychopharmacol 2010; 25 (2): 167–73. 32. Allison KC, Studt SK, Berkowitz RI et al. An open-label efficacy trial of escitalopram for night eating syndrome. Eat Behav 2013; 14 (2): 199–203. 33. Vander Wal JS, Gang CH, Griffing GT, Gadde KM. Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. J Clin Psychopharmacol 2012; 32 (3): 341–5. 34. Calandra C, Gulino V, Inserra L. The use of citalopram in an integrated approach to the treatment of eating disorders: an open study. Eat Weight Disord 1999; 4 (4): 207–10. 35. Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol 2006; 21 (3): 177–9. 36. Muller JE, Wentzel I, Koen L et al. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2008; 23: 43–8. 37. Fineberg NA, Tonnoir B, Lemming O et al. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 2007; 17: 430–9. 38. Grant JE, Potenza MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004; 16 (1): 27–34. 39. Coccaro EF, Kavoussi RJ, Sheline YI et al. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Arch Gen Psychiatry 1996; 53: 531–6. 40. Moreno I, Saiz-Ruiz J, Lopez-Ibor JJ. Serotonin and gambling dependence. Hum Psychopharmacol 1991; 6: 9–12. 41. Blanco C, Orensanz-Muñoz L, Blanco-Jerez C, Saiz-Ruiz J. Pathological gambling and platelet MAO activity: a psychobiological study. Am J Psychiatry 1996; 153: 119–21. 42. Pallanti S, Bernardi S, Allen A, Holander E. Serotonin function in pathological gambling: Blunted growth hormone response to Sumatriptan. J Psychopharmacol 2010; 24 (12): 1902–809. 43. Yip SW, Potenza MN. Treatment of Gambling Disorders. Curr Treat Options Psychiatry 2014; 1 (2): 189–203. 44. Hollander E, Buchalter AJ, DeCaria CM. Pathological gambling. Psychiatr Clin North Am 2000; 23: 629–42. 45. Carrasco JL, Sáiz-Ruiz J, Hollander E et al. Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatr Scand 1994; 90 (6): 427–31. 46. Weinstock J, Ledgerwood DM, Modesto-Lowe V, Petry NM. Ludomania: cross-cultural examinations of gambling and its treatment. [Article in Portuguese]. Rev Bras Psiquiatr 2008; 30 (Suppl. 1:) S3–S10. 47. McCormick RA, Russo AM, Ramirez LF, Taber JI. Affective disorders among pathological gamblers seeking treatment. Am J Psychiatry 1984; 141 (2): 215–8. 48. Linden RD, Pope HG, Jonas JM. Pathological gambling and major affective disorder: preliminary findings. J Clin Psychiatry 1986; 47 (4): 201–3. 49. Taber JI, McCormick RA, Russo AM et al. Follow-up of pathological gamblers after treatment. Am J Psychiatry 1987; 144 (6): 757–61. 50. Hodgins DC, Peden N, Cassidy E. The association between comorbidity and outcome in pathological gambling: a prospective follow-up of recent quitters. J Gambl Stud 2005; 21 (3): 255–71. 51. Dannon PN, Lowengrub K, Gonopolski Y et al. Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder. Prim Care Companion J Clin Psychiatry 2006; 8 (6): 334–9. 52. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 2002; 63 (1): 44–8. 53. Grant JE, Kim SW, Potenza MN. Advances in the pharmacological treatment of pathological gambling. J Gambl Stud 2003; 19 (1): 85–109. 54. Blanco C, Potenza MN, Kim SW et al. A pilot study of impulsivity and compulsivity in pathological gambling. Psychiatry Res 2009; 167 (1–2): 161–8. 55. Bullock S, Potenza MN. Pathological gambling: Neuropsychology and treatment. Curr Psychopharmacol 2012: 167–85. 56. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol 2006; 21 (4): 203–9. 57. Black DW, Shaw M, Forbush KT, Allen J. An open-label trial of escitalopram in the treatment of pathological gambling. Clin Neuropharmacol 2007; 30 (4): 206–12. 58. Rosenberg O, Dinur LK, Dannon PN. Four-year follow-up study of pharmacological treatment in pathological gamblers. Clin Neuropharmacol 2013; 36 (2): 42–5. 59. Myrseth H, Molde H, Støylen IJ et al. A pilot study of CBT versus escitalopram combined with CBT in the treatment of pathological gamblers. Int Gamb Stud 2011; 11 (1): 121–41. 60. Морозов П.В. Эсциталопрам: новые возможности применения. Психиатрия и психофармакотерапия. 2006; 8 (3): 37–8. / Morozov P.V. Estsitalopram: novye vozmozhnosti primeneniia. Psychiatry and Psychopharmacotherapy. 2006; 8 (3): 37–8. [in Russian] 61. Spada MM. An overview of problematic internet use. Addict Behav 2014; 39 (1): 3–6. 62. Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry 2007; 68 (3): 422–7. 63. Gadde KM, Ryan Wagner H 2nd, Connor KM et al. Escitalopram treatment of trichotillomania. Int Clin Psychopharmacol 2007; 22 (1): 39–42. 64. Kahkonen S. Trichotillomania in a schizophrenia patient. CNS Spectr 2002; 7 (10): 751–2. 65. Mittal D, O'Jile J, Kennedy R et al. Trichotillomania associated with dementia: a case report. Gen Hosp Psychiatry 2001; 23 (3): 163–5. 66. Kordon A, Broocks A, Hohagen F. Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair. [Article in German]. MMW Fortschr Med 2003; 145 (Suppl. 2): 4–7. 67. Maity N, Ghosal MK, Gupta A et al. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol 2014; 46 (4): 433–7. 68. Mikami K, Jorge RE, Moser DJ et al. Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy. J Neuropsychiatry Clin Neurosci 2014; 26 (4): 323–8. 69. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17 (2): 65–9. 70. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011; 342: d1199. 71. Lenze EJ, Rollman BL, Shear MK et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA 2009; 301 (3): 295–303. 72. Lele M, Joglekar A. Escitalopram for social anxiety disorder. Br J Psychiatry 2005; 187: 290–1; author reply 291–2. 73. Asakura S, Hayano T, Hagino A, Koyama T. A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan. Curr Med Res Opin 2016; 5: 1–9. 74. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17 (5): 343–62. 75. Choi KW, Woo JM, Kim YR et al. Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial. Clin Psychopharmacol Neurosci 2012; 10 (1): 44–8. 76. Rampello L, Alvano A, Raffaele R et al. New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol 2006; 26: 67–70. 77. Robert S, Hamner MB, Ulmer HG et al. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry 2006; 67 (10): 1522–6. 78. Ramaswamy S, Selvaraj V, Driscoll D et al. Effects of Escitalopram on Autonomic Function in Posttraumatic Stress Disorder Among Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF). Innov Clin Neurosci 2015; 12 (5–6): 13–9. 79. Mikami K, Jorge RE, Moser DJ et al. Prevention of poststroke apathy using escitalopram or problem-solving therapy. Am J Geriatr Psychiatry 2013; 21 (9): 855–62. 80. House A. Escitalopram may improve some cognitive functions after stroke in non-depressed patients. Evid Based Ment Health 2010; 13 (3): 81. 81. Jorge RE, Acion L, Moser D et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 2010; 67 (2): 187–96. 82. LaCroix AZ, Freeman EW, Larson J et al. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas 2012; 73 (4): 361–8. 83. Tsui JI, Herman DS, Kettavong M et al. Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. Pain 2011; 152 (11): 2640–4. 84. Mazza M, Mazza O, Pazzaglia C et al. Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. Expert Opin Pharmacother 2010; 11: 1049–52. 85. Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol 2009; 32 (5): 254–8. 86. Choe YM, Kim KW, Jhoo JH et al. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease. Int J Geriatr Psychiatry 2015. 87. Mitsonis CI, Zervas IM, Potagas CM et al. Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study. Eur Neuropsychopharmacol 2010; 20 (2): 123–31. 88. Korendovych IV, Svintsits'kyĭ AS, Revenok KM, Maliarov SO. Psychopharmacological approach with the usage of selective serotonin reuptake inhibitors in functional dyspepsia treatment. [Article in Ukrainian]. Lik Sprava 2014; 11: 58–64. 89. Tack J, Broekaert D, Fischler B et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55 (8): 1095–103. 90. Viazis N, Karamanolis G, Vienna E et al. Selective-reuptake inhibitors for the treatment of hypersensitive esophagus. Therap Adv Gastroenterol 2011; 4 (5): 295–300. 91. Harish T, Muliyala K, Murthy P. Successful management of vaginismus: An eclectic approach. Indian J Psychiatry 2011; 53 (2): 154–5. 92. D'Erme AM, Zanieri F, Campolmi E et al. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. J Eur Acad Dermatol Venereol 2014; 28 (2): 246–9. 93. Tribó MJ, Andión O, Ros S et al. Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study. Dermatology 2008; 216 (1): 24–30. 94. El-Nour H, Lundeberg L, Abdel-Magid N et al. Serotonergic mechanisms in human allergic contact dermatitis. Acta Derm Venereol 2007; 87 (5): 390–6. 95. Wang Y, Zhang H, Chai F et al. The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. BMC Psychiatry 2014; 14: 349. 96. Blay SL. A case of major depressive disorder and symptoms of polycystic ovary syndrome responding to escitalopram. Prim Care Companion CNS Disord 2011; 13 (6). 97. Bschor T, Ising M, Erbe S et al. Impact of citalopram on the HPA system. A study of the combined DEX/CRH test in 30 unipolar depressed patients. J Psychiatr Res 2012; 46 (1): 111–7. 98. Nehir Aytan A, Bastu E, Demiral I et al. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol 2016; 7: 1–5. 99. Kamarck TW, Muldoon MF, Manuck SB et al. Citalopram improves metabolic risk factors among high hostile adults: results of a placebo-controlled intervention. Psychoneuroendocrinology 2011; 36 (7): 1070–9. 100. Eller T, Metsküla K, Talja I et al. Thyroid autoimmunity and treatment response to escitalopram in major depression. Nord J Psychiatry 2010; 64 (4): 253–7. 101. Белова Н.А. Эсциталопрам (ципралекс) в общей медицине (обзор литepaтуpы). Психические расстройства в общей медицине. 2010; 2: 52–4. / Belova N.A. Estsitalopram (tsipraleks) v obshchei meditsine (obzor litepatupy). Mental Disorders in General Medicine. 2010; 2: 52–4. [in Russian] 102. Halaris A, Myint AM, Savant V et al. Does escitalopram reduce neurotoxicity in major depression? J Psychiatr Res 2015; 66–67: 118–26. 103. Chavda N, Kantharia ND, Jaykaran I. Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. J Pharmacol Pharmacother 2011; 2 (1): 11–6. 104. Erkul E, Cingi C, Özçelik Korkmaz M et al. Effects of escitalopram on symptoms and quality of life in patients with allergic rhinitis. Am J Rhinol Allergy 2012; 26 (5): 142–6. 105. Freeman EW, Sondheimer SJ, Sammel MD et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005; 66 (6): 769–73. 106. Eriksson E, Ekman A, Sinclair S et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 2008; 28 (2): 195–202. 107. Wiśniewska I, Jochymek B, Lenart-Lipińska M et al. The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. Breast Cancer 2016; 23 (2): 178–82. 108. Defronzo Dobkin R, Menza M, Allen LA et al. Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study. Ann Clin Psychiatry 2009; 21 (2): 70–6. 109. Diem SJ, Joffe H, Larson JC et al. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J Clin Endocrinol Metab 2014; 99 (9): 1732–7. 110. Ellebaek E, Herrstedt J. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care 2008; 2 (1): 28–34. 111. Coupland NJ, Bailey JE, Potokar JP et al. 5-HT3 receptors, nausea, and serotonin reuptake inhibition. J Clin Psychopharmacol 1997; 17 (2): 142–3. 112. Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta 2015; 1848 (10 Pt B): 2738–46. 113. Hesketh PJ, Aapro M, Jordan K et al. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int 2015; 2015: 651879. 114. Nothdurfter C, Tanasic S, Di Benedetto B et al. Impact of lipid raft integrity on 5-HT3 receptor function and its modulation by antidepressants. Neuropsychopharmacology 2010; 35 (7): 1510–9. 115. Hothersall JD, Alexander A, Samson AJ et al. 5-Hydroxytryptamine (5-HT) cellular sequestration during chronic exposure delays 5-HT3 receptor resensitization due to its subsequent release. J Biol Chem 2014; 289 (46): 32020–9. 116. Mir O, Durand JP, Boudou-Rouquette P et al. Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. Support Care Cancer 2012; 20 (9): 2235–9. 117. Natale JJ. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. Hosp Pract 2015; 43 (4): 226–34. 118. Bétry C, Overstreet D, Haddjeri N et al. A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant. Pharmacol Biochem Behav 2015; 131: 136–42. 119. Freedman RR, Kruger ML, Tancer ME. Escitalopram treatment of menopausal hot flashes. Menopause 2011; 18 (8): 893–6. 120. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21 (5): 297–309. 121. Van Nieuwenhoven MA, Kilkens TO. The effect of acute serotonergic modulation on rectal motor function in diarrhea-predominant irritable bowel syndrome and healthy controls. Eur J Gastroenterol Hepatol 2012; 24 (11): 1259–65. 122. Shetty S, Hariharan A, Shirole T, Jagtap AG. Neuroprotective potential of escitalopram against behavioral, mitochondrial and oxidative dysfunction induced by 3-nitropropionic acid. Ann Neurosci 2015; 22 (1): 11–8. 123. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322–7. 124. Labuzek K, Beil S, Beil-Gawełczyk J et al. The latest achievements in the pharmacotherapy of gambling disorder. Pharmacol Rep 2014; 66 (5): 811–20. 125. Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram. Clin Pract Epidemiol Ment Health 2006; 2: 35. 126. Бойко В.С., Сулейменова А.А., Садовская А.А. Применения препарата ЭлицеяR в психотерапевтическом отделении республиканского научно-практического центра психиатрии, психотерапии и наркологии. Вестн. КазНМУ. 2015; 2. / Boiko V.S., Suleimenova A.A., Sadovskaia A.A. Primeneniia preparata ElitseiaR v psikhoterapevticheskom otdelenii respublikanskogo nauchno-prakticheskogo tsentra psikhiatrii, psikhoterapii i narkologii. Vestn. KazNMU. 2015; 2. [in Russian] 127. Медведев В.Э. Пострегистрационное исследование безопасности и эффективности препарата Элицея (эсциталопрам) в лечении депрессивных и тревожных расстройств (реферат). Психиатрия и психофармакотерапия. 2013; 15 (4): 65–8. / Medvedev V.E. Postregistraton study of the safety and efficacy of Eliceya (escitalopram) in the treatment of depressive and anxiety disorders (abstract). Psychiatry and Psychopharmacotherapy. 2013; 15 (4): 65–8. [in Russian] 128. Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006; 189: 264–72. 129. DeCaria CM, Hollander E, Grossman R et al. Diagnosis, neurobiology, and treatment of pathological gambling. J Clin Psychiatry 1996; 57 (Suppl. 8): 80–3; discussion 83–4. 130. Kim JM, Stewart R, Bae KY. Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS. Sleep 2015; 38 (7): 1105–11. 131. Pallanti S, Quercioli L, Sood E et al. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63: 559–64. 132. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectr 2015; 20 (5): 455–9.